KALA BIO, Inc. (KALA) stock
Close on Nov 17, 2026Market cap $66.34MP/E –Yield –
Earnings
Kala Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Kala Bio's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2025ended Jun 30, 2025 | Aug 8, 2025before the open | – | – | -$1.71 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 31, 2025before the open | – | – | -$1.74 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | – | – | -$3.16 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 14, 2024during market hours | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 29, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023before the open | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 4, 2023before the open | – | – | -$4.36 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023before the open | – | – | -$6.99 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 3, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022before the open | $400.00K | -87.1% | $19.25 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022before the open | $2.10M | – | -$0.38 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022before the open | $1.40M | – | -$0.45 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 29, 2022before the open | $1.90M | – | -$0.68 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021before the open | $3.10M | – | -$0.43 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 27, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 7, 2020before the open | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Jan 13, 2020before the open | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 7, 2019before the open | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 6, 2019before the open | – | – | – | Filing |
| Q1 FY2019ended Mar 31, 2019 | May 9, 2019before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Kala Bio guided for has been reported
Guidance history
Every forecast Kala Bio put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 8, 2022 | non-GAAP operating expenses | FY2022 | +50% | Reaffirmed |
| Nov 8, 2022 | non-GAAP total operating expenses | FY2023 | +60% – +70% | Reaffirmed |
| Aug 11, 2022 | reduction in non-GAAP operating expenses | FY2022 | +50% | New |
| Aug 11, 2022 | reduction in non-GAAP total operating expenses | FY2023 | +60% – +70% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Kala Bio filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- News
- Update
- Update
- News
- News
- News
- Results
- Results
- Results
- News
- Results
- Results
- News
See a number that looks wrong?